Table 1.
Ongoing trials of ALK1/ENG pathway inhibitors
| Tumor Type | N | Phase | Status | ||
|---|---|---|---|---|---|
| Dalantercept | Squamous Cell Ca | 45 | 2 | Recruiting | |
| Endometrial Ca | 52 | 2 | Recruiting | ||
| Renal Cell Ca | 156 | 2 | Recruiting | ||
| Epithelial Ovarian, Fallopian tube, Primary Peritoneal Ca | 43 | 2 | Recruiting | ||
| Advanced solid tumors, multiple myeloma | 37 | 1 | Completed | ||
| PF-03446962 | Hepatocellular Ca | 180 | 2 | Not yet recruiting | |
| Advanced Solid Tumors | 68 | 1 | Completed | ||
| Transitional Cell Ca of the Bladder | 45 | 2 | Not yet recruiting | ||
| TRC105 | Metastatic Breast Ca | 30 | 1B | Recruiting | |
| Active, not | |||||
| Advanced Solid Tumor | 38 | 1B | recruiting | ||
| Renal Cell Ca | 18 | 1B | Recruiting | ||
| Glioblastoma Multiforme | 128 | 1,2 | Recruiting | ||
| Active, not | |||||
| Advanced Urothelial Carcinoma | 13 | 2 | recruiting | ||
| Glioblastoma Multiforme | 32 | 2 | Recruiting | ||
| Recurrent Ovarian Cancer, Fallopian tube Carcinoma | Active, not | ||||
| Primary Peritoneal Carcinoma | 45 | 2 | recruiting | ||
| Hepatocellular Carcinoma (HCC) | 30 | 2 | Recruiting | ||
| Active, not | |||||
| Metastatic Castrate Resistant Prostate Cancer | 21 | 1,2 | recruiting | ||
| Hepatocellular Carcinoma (HCC) | 72 | 1,2 | Recruiting | ||
| Advanced Solid Cancer | 51 | 1 | Completed | ||
| Glioblastoma Multiforme | 22 | 2 | Recruiting | ||
| Advanced Renal Cell Carcinoma | 88 | 2 | Recruiting | ||